

Study Number: C12005-01
Test Type: TOX
Route: Oral Gavage
Species/Strain: Rat/Harlan Sprague Dawley

PA43: Hematology Summary
Test Compound: Octrizole
CAS Number: 3147-75-9

Date Report Requested: 04/08/2026
Time Report Requested: 15:16:58
Lab: Battelle

Study Number: C12005-01
Study Sex: Male
PWG Approval Date: See web page for date of PWG Approval
Version: v1.7.4
Stat Version: 2023.02.27S

Study Number: C12005-01

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Harlan Sprague Dawley

PA43: Hematology Summary

Test Compound: Octrizole

CAS Number: 3147-75-9

Date Report Requested: 04/08/2026

Time Report Requested: 15:16:58

Lab: Battelle

Male													
Treatment Groups (mg/kg)													
	Phase Day	0			30			100			300		
Hematocrit (%)	SD 14	51.1	± 0.3	(5)	51.7	± 0.3	(3)	50.8	± 1.1	(5)	51.5	± 0.4	(5)
Percent of Control					101.2			99.4			100.8		
Manual Hematocrit (%)	SD 14	50.2	± 0.6	(5)	48.7	± 0.7	(3)	48.4	± 0.7	(5)	49.4	± 0.5	(5)
Percent of Control					96.9			96.4			98.4		
Hemoglobin (g/dL)	SD 14	15.7	± 0.2	(5)	16.1	± 0.0	(3)	15.7	± 0.5	(5)	16.2	± 0.1	(5)
Percent of Control					102.3			99.7			102.7		
Erythrocytes (10 ⁶ /uL)	SD 14	8.97	± 0.18	(5)	9.00	± 0.20	(3)	8.95	± 0.28	(5)	9.19	± 0.10	(5)
Percent of Control					100.3			99.8			102.4		
Reticulocytes (10 ³ /uL)	SD 14	212.4	± 10.4	(5)	235.9	± 15.1	(3)	262.4	± 58.9	(5)	228.1	± 8.1	(5)
Percent of Control					111.1			123.5			107.4		
Mean Cell Volume (fL)	SD 14	57.0	± 0.9	(5)	57.5	± 0.9	(3)	56.8	± 0.7	(5)	56.1	± 0.6	(5)
Percent of Control					100.8			99.6			98.3		
Mean Cell Hemoglobin (pg)	SD 14	17.6	± 0.3	(5)	17.9	± 0.4	(3)	17.5	± 0.1	(5)	17.6	± 0.2	(5)
Percent of Control					102.1			99.9			100.2		
Mean Cell Hemoglobin Concentration (g/dL)	SD 14	30.8	± 0.4	(5)	31.2	± 0.2	(3)	30.9	± 0.4	(5)	31.3	± 0.1	(5)
Percent of Control					101.1			100.3			101.7		
Platelets (10 ³ /uL)	SD 14	792	± 61	(5)	684	± 87	(3)	925	± 180	(5)	884	± 87	(5)
Percent of Control					86.4			116.8			111.7		
White Blood Cells (10 ³ /uL)	SD 14	11.82	± 0.76	(5)	11.17	± 0.23	(3)	14.10	± 0.93	(5)	10.81	± 0.76	(5)
Percent of Control					94.5			119.2			91.5		
Neutrophils (10 ³ /uL)	SD 14	1.42	± 0.15	(5)	1.51	± 0.29	(3)	3.93	± 1.42	(5)	1.34	± 0.10	(5)
Percent of Control					106.2			276.7			94.5		

Study Number: C12005-01
Test Type: TOX
Route: Oral Gavage
Species/Strain: Rat/Harlan Sprague Dawley

PA43: Hematology Summary
Test Compound: Octrizole
CAS Number: 3147-75-9

Date Report Requested: 04/08/2026
Time Report Requested: 15:16:58
Lab: Battelle

Male						
		Treatment Groups (mg/kg)				
	Phase Day	0	30	100	300	
Lymphocytes (10 ³ /uL)	SD 14	9.70 ± 0.54 (5)	9.03 ± 0.57 (3)	9.12 ± 1.12 (5)	8.93 ± 0.62 (5)	
Percent of Control			93.2	94.1	92.1	
Monocytes (10 ³ /uL)	SD 14	0.45 ± 0.07 (5)	0.35 ± 0.08 (3)	0.66 ± 0.21 (5)	0.32 ± 0.06 (5)	
Percent of Control			76.7	145.1	69.9	
Basophils (10 ³ /uL)	SD 14	0.06 ± 0.01 (5) *	0.05 ± 0.00 (3)	0.05 ± 0.00 (5)	0.04 ± 0.01 (5)	
Percent of Control			95.2	89.3	71.4	
Eosinophils (10 ³ /uL)	SD 14	0.11 ± 0.03 (5)	0.14 ± 0.02 (3)	0.21 ± 0.10 (5)	0.12 ± 0.02 (5)	
Percent of Control			130.3	187.3	105.5	
Large Unstained Cells (10 ³ /uL)	SD 14	0.09 ± 0.01 (5)	0.09 ± 0.01 (3)	0.13 ± 0.03 (5)	0.07 ± 0.01 (5)	
Percent of Control			96.3	146.7	77.8	

Study Number: C12005-01
Test Type: TOX
Route: Oral Gavage
Species/Strain: Rat/Harlan Sprague Dawley

PA43: Hematology Summary
Test Compound: Octrizole
CAS Number: 3147-75-9

Date Report Requested: 04/08/2026
Time Report Requested: 15:16:58
Lab: Battelle

Male

		Treatment Groups		
	Phase Day	1000		
Hematocrit (%)	SD 14	50.6 ± 0.4	(5)	
Percent of Control		99.0		
Manual Hematocrit (%)	SD 14	49.4 ± 0.4	(5)	
Percent of Control		98.4		
Hemoglobin (g/dL)	SD 14	15.8 ± 0.1	(5)	
Percent of Control		100.3		
Erythrocytes (10 ⁶ /uL)	SD 14	8.85 ± 0.09	(5)	
Percent of Control		98.6		
Reticulocytes (10 ³ /uL)	SD 14	206.3 ± 8.2	(5)	
Percent of Control		97.1		
Mean Cell Volume (fL)	SD 14	57.2 ± 0.3	(5)	
Percent of Control		100.2		
Mean Cell Hemoglobin (pg)	SD 14	17.8 ± 0.1	(5)	
Percent of Control		101.6		
Mean Cell Hemoglobin Concentration (g/dL)	SD 14	31.2 ± 0.2	(5)	
Percent of Control		101.1		
Platelets (10 ³ /uL)	SD 14	924 ± 63	(5)	
Percent of Control		116.7		
White Blood Cells (10 ³ /uL)	SD 14	11.58 ± 1.11	(5)	
Percent of Control		98.0		
Neutrophils (10 ³ /uL)	SD 14	1.19 ± 0.23	(5)	
Percent of Control		83.5		

Male		
Treatment Groups		
	Phase Day	1000
Lymphocytes (10 ³ /uL)	SD 14	9.90 ± 0.82 (5)
Percent of Control		102.1
Monocytes (10 ³ /uL)	SD 14	0.29 ± 0.05 (5)
Percent of Control		64.2
Basophils (10 ³ /uL)	SD 14	0.04 ± 0.01 (5)
Percent of Control		71.4
Eosinophils (10 ³ /uL)	SD 14	0.09 ± 0.03 (5)
Percent of Control		80.0
Large Unstained Cells (10 ³ /uL)	SD 14	0.08 ± 0.01 (5)
Percent of Control		86.7

Study Number: C12005-01

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Harlan Sprague Dawley

PA43: Hematology Summary

Test Compound: Octrizole

CAS Number: 3147-75-9

Date Report Requested: 04/08/2026

Time Report Requested: 15:16:58

Lab: Battelle

LEGEND

Values given as mean $\pm$ SEM (N) with Percent of Control calculated by (dosed group mean / control group mean) x 100.

SD = Study Day

Statistical analysis was performed by Jonckheere (trend) and Shirley or Dunn (pairwise) tests.

Statistical significance for the control group indicates a significant trend test.

Statistical significance for a treatment group indicates a significant pairwise test compared to the vehicle control group.

* Statistically significant at $p \leq 0.05$

** Statistically significant at $p \leq 0.01$

SEM = Standard Error of the Mean

Hematology data not reported was removed as an outlier, or was due to pre-analytical or analytical conditions or errors including but not limited to: short sample, quantity not sufficient, or clotted sample.

**** END OF REPORT ****